| VTRS |
Report |
Q2 2026 Total Revenue |
BEAT |
pred ~$3.56B vs. cons $3.50B |
MEDIUM |
| VTRS |
Report |
Q2 2026 Adjusted EPS |
BEAT |
pred ~$0.58 vs. cons $0.56 |
MEDIUM |
| VTRS |
Report |
Q2 2026 Adjusted EBITDA |
BEAT |
pred ~$1.03B vs. cons $1.00B |
MEDIUM |
| VTRS |
Guide |
FY2026 Revenue Guidance |
UNCHANGED |
guide ~$14.70B (reaffirmed midpoint, $14.45-14.95B range) vs. cons $14.70B (FY2026) |
HIGH |
| VTRS |
Guide |
FY2026 Adjusted EPS Guidance |
UNCHANGED |
guide ~$2.40 (reaffirmed midpoint, $2.33-2.47 range) vs. cons $2.40 (FY2026) |
HIGH |
| VTRS |
Guide |
New Product Revenue Ramp ($450-550M target) |
UNKNOWN |
guide ~$500B midpoint reiterated vs. cons ~$500M (FY2026, heavily H2-weighted after only ~$71M in Q1) |
LOW |
| VTRS |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.0% |
— |
MEDIUM |
| VTRS |
Return |
5-day cumulative residual |
-3.5% (FADE) |
Stock has already run from ~$15 to ~$17.7 (+18%) since Q1 on China acceleration, Gwyn Lo approval, Biocon monetization and multiple sell-side PT hikes, so most incremental good news is priced in. Management's established pattern is 'beat-and-hold' (Q1 was reaffirmed, not raised, despite an 18% China beat), so a second straight quarter of reaffirmed-not-raised FY26 guidance despite decent Q2 numbers likely disappoints a market positioned for a raise. With guidance still implying ~52% H2 weighting and only ~$71M of the $450-550M new-product target booked through Q1, the out-period math requires a large H2 ramp; absent explicit upward guidance revision, analysts are likely to trim H2 estimates at the margin even after an in-line-to-modest Q2 beat, producing a fade rather than follow-through over the next week, compounded by lingering overhangs (ARV supply, Europe/JANZ softness, tariff phase-in optics). |
LOW |